How it works:
Remdesivir is an inhibitor of RNA-dependent RNA polymerase, interfering with viral replication inside infected cells. Its rapid onset and good lung tissue penetration make it effective in reducing disease duration and risk of complications in hospitalised patients.
Recommended for:
Adults and adolescents (12 years and older, ≥40 kg)
Patients hospitalised with confirmed COVID-19
Cases with viral pneumonia requiring supplemental oxygen
When intensive antiviral therapy is indicated by physician
Treatment of COVID-19 in hospitalised patients
Supportive antiviral treatment for severe respiratory viral infections
Administered via IV infusion following a standard protocol: loading dose of 200 mg on Day 1, followed by 100 mg once daily for 4–9 additional days. Duration and dosage are determined by the physician based on severity and patient-specific factors.
Contraindications:
Hypersensitivity to remdesivir
Severe hepatic impairment
Children under 12 years of age or body weight below 40 kg
Concurrent use with nephrotoxic agents (use with caution)
Side effects:
Elevated liver enzymes (ALT, AST)
Nausea, headache
Allergic reactions (rash, itching, anaphylaxis)
Renal dysfunction
Hypotension, respiratory difficulties (rare)
